Sudeep Pharma: Business Overview & Financial Analysis
Sudeep Pharma is a technology-led specialty ingredients and excipients manufacturing enterprise headquartered in Vadodara, Gujarat. Promoted by the Bhayani family, the company manufactures mineral actives, specialty excipients, food fortificants, and battery materials for pharmaceutical, food & nutrition, personal care, and energy storage sectors. Sudeep Pharma operates four manufacturing facilities in India with a combined capacity of ~123,000 MT per annum, supplying Fortune 500 multinationals and leading domestic players across 50+ countries.
Revenue Mix by Business Division of Sudeep Pharma (FY2026)
Sudeep Pharma structures its operational turnover across specialty excipients, mineral actives, nutrition ingredients, and battery material development.
- Excipients & Mineral Actives Division – 62.0% of Total Operating Revenue
- Food & Nutrition Ingredients Division – 38.0% of Total Operating Revenue
- Total Consolidated Revenue from Operations (FY2026) – Rs 642.30 crore (+25.6% YoY)
Specialty excipients and mineral actives serve as the primary revenue and margin driver, supplying Calcium, Magnesium, Zinc, and Sodium-based ingredients for solid oral dosages and liquid formulations. Food and nutrition ingredients provide diversification via micronutrient premixes and fortificants.
Geographic Revenue Mix & Export Footprint of Sudeep Pharma (Q1 FY2027)
Sudeep Pharma balances direct domestic supply to Indian pharmaceutical majors with exports across North America, Europe, and Asia-Pacific.
- Domestic Indian Market Sales Share – 57.0% of Total Operating Revenue
- Overseas International Exports Channel Share – 43.0% of Total Operating Revenue
- Active Overseas Client Footprint – Exports to 50+ countries globally
- Overseas Direct Sales Offices – Active sales and distribution hubs in USA (New Jersey) and Europe (Netherlands)
Domestic market sales generate over half of operational turnover, supplying leading pharmaceutical and FMCG formulation plants. Direct overseas sales offices in New Jersey and the Netherlands accelerate export dispatches to international regulated markets.
Manufacturing Facilities & Installed Capacity Scale of Sudeep Pharma (FY2026)
Sudeep Pharma operates specialized chemistry plants equipped with automated spray dryers, fluid bed processors, and chemical synthesis reactors.
- Total Operating Manufacturing Facilities Base – 4 operational manufacturing units in India (Vadodara/Nandesari)
- Installed Manufacturing Capacity Base – 72,246 Metric Tonnes Per Annum (MTPA)
- Total Planned Capacity (Post-Expansion) – 123,446 Metric Tonnes Per Annum (MTPA)
- Global Regulatory Site Certifications – USFDA-registered, EXCiPACT, FSSC 22000, WHO-GMP, and ISO-certified sites
- Proprietary Technology Suites – 6 in-house developed technologies for specialty mineral synthesis
Operating four manufacturing sites in Gujarat supports high-volume synthesis of mineral salts and excipients. In-house technological suites enable tight control over particle size, bulk density, and purity standards required by global regulators.
Client Concentration & Key Customer Profile of Sudeep Pharma (FY2026)
Sudeep Pharma maintains multi-decade supply relationships with global healthcare, nutrition, and FMCG brand owners.
- Top 10 Customer Revenue Contribution – 32.0% of Total Operating Revenue
- Fortune 500 Clients Covered – Direct supplier to 14 Fortune 500 corporations
- Customer Relationship Longevity – 15+ years average tenure with core top-tier customers
Revenue concentration remains well-balanced, with the top 10 customers accounting for 32% of total operational turnover. Direct vendor approvals from 14 Fortune 500 companies create high switching costs and stable recurring order pipelines.
Latest Quarterly Financial Performance of Sudeep Pharma (Q1 FY2027)
Sudeep Pharma recorded top-line revenue expansion and net profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 158.30 crore (+26.7% YoY)
- Consolidated Operating EBITDA – Rs 54.90 crore (+25.1% YoY)
- Operating EBITDA Margin – 34.68%
- Consolidated Net Profit After Tax (PAT) – Rs 43.90 crore (+27.2% YoY)
First-quarter operating revenue rose 26.7% year-on-year to Rs 158.30 crore, supported by specialty excipient dispatches to export channels. Consolidated Net Profit After Tax reached Rs 43.90 crore, while operating EBITDA margins held firm at 34.68%.
Standalone & Consolidated Annual Financial Performance of Sudeep Pharma (FY2026)
Sudeep Pharma delivered full-year operational turnover expansion and operating profit growth for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 642.30 crore (+25.6% YoY)
- Full Year Operating EBITDA – Rs 222.10 crore (+27.4% YoY)
- Full Year Operating EBITDA Margin – 34.58%
- Consolidated Net Profit After Tax (PAT) – Rs 174.20 crore (+25.6% YoY)
- Return on Capital Employed (ROCE) – 22.5%
- Return on Equity (ROE) – 19.4%
Full-year operating turnover crossed Rs 640 crore in FY2026, as consolidated Net Profit After Tax reached Rs 174.20 crore. Financial performance was driven by export volume growth, product mix optimization, and operating leverage across Vadodara facilities.
Balance Sheet Structure & Financial Health Ratios of Sudeep Pharma (Q1 FY2027)
Sudeep Pharma operates a disciplined capital structure supported by low debt gearing and strong operating cash flow generation.
- Net Financial Debt to Equity Ratio – Low Debt (0.16x)
- Total Cash, Bank Balances & Liquid Treasury Investments – Rs 180.00 crore
- Total Consolidated Net Worth Base – Rs 898.00 crore
- Return on Equity (ROE) – 19.4%
- Working Capital Cycle – 89 days
Consolidated net worth expanded to Rs 898.00 crore, with debt to equity holding low at 0.16x. Cash reserves and internal operational cash flows support capital expenditure outlays without stretching balance sheet leverage.
Subsidiary Expansion & Battery Materials Roadmap via Sudeep Advanced Materials (FY2027–FY2028)
Sudeep Pharma executes capital allocation plans through its wholly owned subsidiary, Sudeep Advanced Materials (SAM), to enter green energy supply chains.
- Strategic Subsidiary Entity – Sudeep Advanced Materials Private Limited (100% Wholly Owned Subsidiary)
- Target Vertical Focus – Sustainable battery materials, precursor chemicals, and energy storage ingredients
- Phase 1 Facility Commissioning Timeline – On track for commercial commissioning by March 2027
- Commercial Offtake Agreements – Signed 2 additional strategic MoUs during Q1 FY2027 with global battery developers
- Funding Strategy – 100% funded through internal operational cash accruals and liquid reserves
Phase 1 of Sudeep Advanced Materials is targeted for commercial commissioning by March 2027 to manufacture battery precursor chemicals. Executing two new MoUs during Q1 FY2027 validates client qualifications for Phase 2 planning.
Strategic Outlook & Management Commentary of Sudeep Pharma (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on specialty excipient capacity scaling, export market penetration, and battery material commercialization.
- Management targets maintaining a 20%–25% annual top-line revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain around the 33.0%–35.0% corridor through high-value product mix execution.
- Excipient manufacturing capacity will be expanded from 72,246 MTPA toward 123,446 MTPA to meet global customer orders.
- Sudeep Advanced Materials Phase 1 will be commercialized by March 2027 to capture EV and energy storage demand.
- Capital allocation strategy will maintain a conservative debt-to-equity ratio under 0.25x while funding greenfield expansions.
Management anticipates rising global demand for certified pharmaceutical excipients and mineral fortificants to support top-line execution. Operational focus centers on completing the Phase 1 battery materials plant, scaling European and US sales hubs, and preserving balance sheet health.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Sudeep Pharma Q1 FY2027 Consolidated Financial Results Disclosures & Investor Presentation (August 2026)
- Sudeep Pharma Stock Exchange Disclosures & NSE Outcome Filings (February/May 2026)
- Sudeep Pharma Investor Meet Schedule & Corporate Filings (March 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Sudeep Pharma
- Ticker Finology Sudeep Pharma Page
Disclaimer
The information presented above on Sudeep Pharma has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Sudeep Pharma page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.